XTX Topco Ltd Trims Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

XTX Topco Ltd trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 43.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,722 shares of the company's stock after selling 2,818 shares during the period. XTX Topco Ltd's holdings in Medpace were worth $1,237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. R Squared Ltd bought a new position in shares of Medpace during the fourth quarter valued at $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace during the 4th quarter worth $31,000. Jones Financial Companies Lllp boosted its holdings in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares during the period. Lindbrook Capital LLC grew its holdings in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares in the last quarter. Finally, Assetmark Inc. lifted its position in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MEDP has been the topic of several research analyst reports. Leerink Partnrs upgraded Medpace to a "hold" rating in a research note on Monday, March 24th. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target for the company. Mizuho dropped their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research report on Wednesday, April 9th. TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and reduced their price objective for the company from $370.00 to $328.00 in a research note on Monday. Finally, Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Ten equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Medpace currently has a consensus rating of "Hold" and an average target price of $357.50.

Medpace Price Performance

MEDP stock traded down $0.22 during trading on Friday, reaching $296.28. The company had a trading volume of 698,291 shares, compared to its average volume of 325,409. Medpace Holdings, Inc. has a 52 week low of $272.00 and a 52 week high of $459.77. The company has a market cap of $8.96 billion, a P/E ratio of 23.46, a PEG ratio of 3.81 and a beta of 1.46. The business has a 50 day moving average of $319.15 and a 200 day moving average of $333.57.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.